Global Leader in Cancer Vaccines: US Continues to Surge on Growth Path

US currently holds a 49% share in the global cancer vaccines market and continues to experience robust growth opportunities, says RNCOS.

NOIDA, India (prHWY.com) January 9, 2013 - A new research report from RNCOS shows that the US is in the lead for cancer vaccines and accounts for a robust share of 49% in the global market. The market continues to surge for even greater developments backed by active funding and support by both the government and private players. Both the prophylactic and therapeutic vaccines are in a promising position in the US market. In particular government support has been observed to prophylactic cancer vaccines as a remedy for the high mortality of cervical cancer in females. Therapeutic cancer vaccines holds great promise due to the large number of candidates in clinical trials. On the competitive front, both Merck and GSK are expected to continue to hold a dominant position.

The research and innovation for cancer vaccines is highly robust and several candidates are being studied for their role in cancer with surprisingly large number of trials focused on the therapeutic vaccines. With growing diseases and requirement for specialized drugs and vaccines as a major driver, the share of therapeutic vaccines is expected to grow by 15% in 2012. The current marketed product portfolio includes Merck's Gardasil, GSK's Cervarix, and several other Hepatitis B vaccines while the only therapeutic vaccine in the market is Dendreon's Provenge. In terms of state level market opportunity, California ranks top in the total number of new cancer cases followed by Florida, Texas and New York representing a promising market for cancer vaccines.

The report entitled, "US Cancer Vaccine Market Analysis", provides an analysis of the market drivers, current market size, and future estimates. It also provides the key constraints faced by these cancer vaccine products that can hinder its market growth in the future. Moreover, an in-depth analysis of all the candidate cancer vaccines in various phases of clinical trials for highly prevalent cancers in the US has been covered to identify opportunities for players. Further, the report provides competitive analysis of the promising players in the market along with their key strategies for business expansion. The regulatory environment detailing the whole cancer vaccine approval process along with FDA's guidelines to the industry for clinical proceedings of cancer therapeutic vaccines has also been covered in this report.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM457.htm

Some of our Related Reports are:

- Global Vaccine Market Forecast to 2013 (http://www.rncos.com/Report/IM357.htm)
- Global Influenza Vaccine Market Analysis (http://www.rncos.com/Report/IM356.htm)
- Global Vaccine Market Forecast to 2012 (http://www.rncos.com/Report/IM153.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

###

Tag Words: cancer vaccine market

Categories: Health

Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707

Link To This Press Release:

URL HTML Code